These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
366 related articles for article (PubMed ID: 28533225)
1. Multifunctional Effects of a Small-Molecule STAT3 Inhibitor on NASH and Hepatocellular Carcinoma in Mice. Jung KH; Yoo W; Stevenson HL; Deshpande D; Shen H; Gagea M; Yoo SY; Wang J; Eckols TK; Bharadwaj U; Tweardy DJ; Beretta L Clin Cancer Res; 2017 Sep; 23(18):5537-5546. PubMed ID: 28533225 [No Abstract] [Full Text] [Related]
2. Small-molecule inhibition of STAT3 in radioresistant head and neck squamous cell carcinoma. Bharadwaj U; Eckols TK; Xu X; Kasembeli MM; Chen Y; Adachi M; Song Y; Mo Q; Lai SY; Tweardy DJ Oncotarget; 2016 May; 7(18):26307-30. PubMed ID: 27027445 [TBL] [Abstract][Full Text] [Related]
3. LLL12, a novel small inhibitor targeting STAT3 for hepatocellular carcinoma therapy. Zuo M; Li C; Lin J; Javle M Oncotarget; 2015 May; 6(13):10940-9. PubMed ID: 25883212 [TBL] [Abstract][Full Text] [Related]
4. C188-9, a small-molecule STAT3 inhibitor, exerts an antitumor effect on head and neck squamous cell carcinoma. Di JX; Zhang HY Anticancer Drugs; 2019 Sep; 30(8):846-853. PubMed ID: 30870229 [TBL] [Abstract][Full Text] [Related]
5. Ezetimibe suppresses development of liver tumors by inhibiting angiogenesis in mice fed a high-fat diet. Miura K; Ohnishi H; Morimoto N; Minami S; Ishioka M; Watanabe S; Tsukui M; Takaoka Y; Nomoto H; Isoda N; Yamamoto H Cancer Sci; 2019 Feb; 110(2):771-783. PubMed ID: 30520543 [TBL] [Abstract][Full Text] [Related]
6. Activation of FXR modulates SOCS3/Jak2/STAT3 signaling axis in a NASH-dependent hepatocellular carcinoma animal model. Attia YM; Tawfiq RA; Gibriel AA; Ali AA; Kassem DH; Hammam OA; Elmazar MM Biochem Pharmacol; 2021 Apr; 186():114497. PubMed ID: 33675775 [TBL] [Abstract][Full Text] [Related]
7. Inflammatory microenvironment of fibrotic liver promotes hepatocellular carcinoma growth, metastasis and sorafenib resistance through STAT3 activation. Jiang Y; Chen P; Hu K; Dai G; Li J; Zheng D; Yuan H; He L; Xie P; Tu M; Peng S; Qu C; Lin W; Chung RT; Hong J J Cell Mol Med; 2021 Feb; 25(3):1568-1582. PubMed ID: 33410581 [TBL] [Abstract][Full Text] [Related]
8. Blocking the CCL2-CCR2 Axis Using CCL2-Neutralizing Antibody Is an Effective Therapy for Hepatocellular Cancer in a Mouse Model. Teng KY; Han J; Zhang X; Hsu SH; He S; Wani NA; Barajas JM; Snyder LA; Frankel WL; Caligiuri MA; Jacob ST; Yu J; Ghoshal K Mol Cancer Ther; 2017 Feb; 16(2):312-322. PubMed ID: 27980102 [TBL] [Abstract][Full Text] [Related]
9. Inhibition of growth and metastasis of human hepatocellular carcinoma by antisense oligonucleotide targeting signal transducer and activator of transcription 3. Li WC; Ye SL; Sun RX; Liu YK; Tang ZY; Kim Y; Karras JG; Zhang H Clin Cancer Res; 2006 Dec; 12(23):7140-8. PubMed ID: 17145839 [TBL] [Abstract][Full Text] [Related]
10. Analysis and Validation of Human Targets and Treatments Using a Hepatocellular Carcinoma-Immune Humanized Mouse Model. Zhao Y; Wang J; Liu WN; Fong SY; Shuen TWH; Liu M; Harden S; Tan SY; Cheng JY; Tan WWS; Chan JKY; Chee CE; Lee GH; Toh HC; Lim SG; Wan Y; Chen Q Hepatology; 2021 Sep; 74(3):1395-1410. PubMed ID: 33738839 [TBL] [Abstract][Full Text] [Related]
11. Quercetin shows anti-tumor effect in hepatocellular carcinoma LM3 cells by abrogating JAK2/STAT3 signaling pathway. Wu L; Li J; Liu T; Li S; Feng J; Yu Q; Zhang J; Chen J; Zhou Y; Ji J; Chen K; Mao Y; Wang F; Dai W; Fan X; Wu J; Guo C Cancer Med; 2019 Aug; 8(10):4806-4820. PubMed ID: 31273958 [TBL] [Abstract][Full Text] [Related]
12. Inhibition of STAT3 signaling pathway by ursolic acid suppresses growth of hepatocellular carcinoma. Liu T; Ma H; Shi W; Duan J; Wang Y; Zhang C; Li C; Lin J; Li S; Lv J; Lin L Int J Oncol; 2017 Aug; 51(2):555-562. PubMed ID: 28714512 [TBL] [Abstract][Full Text] [Related]
13. Nitidine chloride inhibits hepatocellular carcinoma cell growth in vivo through the suppression of the JAK1/STAT3 signaling pathway. Liao J; Xu T; Zheng JX; Lin JM; Cai QY; Yu DB; Peng J Int J Mol Med; 2013 Jul; 32(1):79-84. PubMed ID: 23613111 [TBL] [Abstract][Full Text] [Related]
14. Rheum palmatum extract exerts anti-hepatocellular carcinoma effects by inhibiting signal transducer and activator of transcription 3 signaling. Tan ZB; Fan HJ; Wu YT; Xie LP; Bi YM; Xu HL; Chen HM; Li J; Liu B; Zhou YC J Ethnopharmacol; 2019 Mar; 232():62-72. PubMed ID: 30553869 [TBL] [Abstract][Full Text] [Related]
17. NSC 74859-mediated inhibition of STAT3 enhances the anti-proliferative activity of cetuximab in hepatocellular carcinoma. Chen W; Shen X; Xia X; Xu G; Ma T; Bai X; Liang T Liver Int; 2012 Jan; 32(1):70-7. PubMed ID: 22098470 [TBL] [Abstract][Full Text] [Related]
18. Notch Inhibitor PF-03084014 Inhibits Hepatocellular Carcinoma Growth and Metastasis via Suppression of Cancer Stemness due to Reduced Activation of Notch1-Stat3. Wu CX; Xu A; Zhang CC; Olson P; Chen L; Lee TK; Cheung TT; Lo CM; Wang XQ Mol Cancer Ther; 2017 Aug; 16(8):1531-1543. PubMed ID: 28522590 [TBL] [Abstract][Full Text] [Related]
19. Gemcabene downregulates inflammatory, lipid-altering and cell-signaling genes in the STAM™ model of NASH. Oniciu DC; Hashiguchi T; Shibazaki Y; Bisgaier CL PLoS One; 2018; 13(5):e0194568. PubMed ID: 29847555 [TBL] [Abstract][Full Text] [Related]
20. A Regulatory Role of Apoptosis Antagonizing Transcription Factor in the Pathogenesis of Nonalcoholic Fatty Liver Disease and Hepatocellular Carcinoma. Kumar DP; Santhekadur PK; Seneshaw M; Mirshahi F; Uram-Tuculescu C; Sanyal AJ Hepatology; 2019 Apr; 69(4):1520-1534. PubMed ID: 30394550 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]